Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma

T. Martin, J. Mikhael, R. Hajek, K. Kim, K. Suzuki, C. Hulin, M. Garg, H. Quach, H. Sia, A. George, T. Konstantinova, ML. Risse, G. Asset, S. Macé, H. van de Velde, P. Moreau

. 2022 ; 6 (15) : 4506-4515. [pub] 20220809

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024866

The IKEMA study (Randomized, Open Label, Multicenter Study Assessing the Clinical Benefit of Isatuximab Combined With Carfilzomib [Kyprolis®] and Dexamethasone Versus Carfilzomib With Dexamethasone in Patients With Relapse and/or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines; #NCT03275285) was a randomized, open-label, multicenter phase 3 study investigating isatuximab plus carfilzomib and dexamethasone (Isa-Kd) vs Kd in patients with relapsed multiple myeloma. This subanalysis analyzed the depth of response of Isa-Kd vs Kd. The primary end point was progression-free survival (PFS); secondary end points included overall response rate, very good partial response or better (≥VGPR) rate, complete response (CR) rate, and minimal residual disease (MRD) negativity rate (assessed in patients with ≥VGPR by next-generation sequencing at a 10-5 sensitivity level). At a median follow-up of 20.7 months, deeper responses were observed in the Isa-Kd arm vs the Kd arm, with ≥VGPR 72.6% vs 56.1% and CR of 39.7% vs 27.6%, respectively. MRD negativity occurred in 53 (29.6%) of 179 patients in the Isa-Kd arm vs 16 (13.0%) of 123 patients in the Kd arm, with 20.1% (Isa-Kd, 36 of 179 patients) vs 10.6% (Kd, 13 of 123 patients) reaching MRD-negative CR status. Achieving MRD negativity resulted in better PFS in both arms. A positive PFS treatment effect was seen with Isa-Kd in both MRD-negative patients (hazard ratio, 0.578; 95% CI, 0.052-6.405) and MRD-positive patients (hazard ratio, 0.670; 95% CI, 0.452-0.993). Exploratory analysis indicates that both current CR and MRD-negative CR rates are underestimated due to M-protein interference (potential adjusted CR rate, 45.8%; potential adjusted MRD-negative CR rate, 24.0%). In conclusion, there was a clinically meaningful improvement in depth of response with Isa-Kd. The CR rate in Isa-Kd was 39.7%. Mass spectrometry suggests that the potential adjusted CR rate could reach an unprecedented 45.8% of patients treated with Isa-Kd.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024866
003      
CZ-PrNML
005      
20221031101306.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2021006713 $2 doi
035    __
$a (PubMed)35594559
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Martin, Thomas $u Department of Medicine, University of California, San Francisco, CA
245    10
$a Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma / $c T. Martin, J. Mikhael, R. Hajek, K. Kim, K. Suzuki, C. Hulin, M. Garg, H. Quach, H. Sia, A. George, T. Konstantinova, ML. Risse, G. Asset, S. Macé, H. van de Velde, P. Moreau
520    9_
$a The IKEMA study (Randomized, Open Label, Multicenter Study Assessing the Clinical Benefit of Isatuximab Combined With Carfilzomib [Kyprolis®] and Dexamethasone Versus Carfilzomib With Dexamethasone in Patients With Relapse and/or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines; #NCT03275285) was a randomized, open-label, multicenter phase 3 study investigating isatuximab plus carfilzomib and dexamethasone (Isa-Kd) vs Kd in patients with relapsed multiple myeloma. This subanalysis analyzed the depth of response of Isa-Kd vs Kd. The primary end point was progression-free survival (PFS); secondary end points included overall response rate, very good partial response or better (≥VGPR) rate, complete response (CR) rate, and minimal residual disease (MRD) negativity rate (assessed in patients with ≥VGPR by next-generation sequencing at a 10-5 sensitivity level). At a median follow-up of 20.7 months, deeper responses were observed in the Isa-Kd arm vs the Kd arm, with ≥VGPR 72.6% vs 56.1% and CR of 39.7% vs 27.6%, respectively. MRD negativity occurred in 53 (29.6%) of 179 patients in the Isa-Kd arm vs 16 (13.0%) of 123 patients in the Kd arm, with 20.1% (Isa-Kd, 36 of 179 patients) vs 10.6% (Kd, 13 of 123 patients) reaching MRD-negative CR status. Achieving MRD negativity resulted in better PFS in both arms. A positive PFS treatment effect was seen with Isa-Kd in both MRD-negative patients (hazard ratio, 0.578; 95% CI, 0.052-6.405) and MRD-positive patients (hazard ratio, 0.670; 95% CI, 0.452-0.993). Exploratory analysis indicates that both current CR and MRD-negative CR rates are underestimated due to M-protein interference (potential adjusted CR rate, 45.8%; potential adjusted MRD-negative CR rate, 24.0%). In conclusion, there was a clinically meaningful improvement in depth of response with Isa-Kd. The CR rate in Isa-Kd was 39.7%. Mass spectrometry suggests that the potential adjusted CR rate could reach an unprecedented 45.8% of patients treated with Isa-Kd.
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    _2
$a dexamethason $x terapeutické užití $7 D003907
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x terapie $7 D009101
650    _2
$a lokální recidiva nádoru $x farmakoterapie $7 D009364
650    _2
$a reziduální nádor $x farmakoterapie $7 D018365
650    _2
$a oligopeptidy $7 D009842
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mikhael, Joseph $u Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ $1 https://orcid.org/0000000196702864
700    1_
$a Hajek, Roman $u Department of Hemato-Oncology, University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000169556267
700    1_
$a Kim, Kihyun $u Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
700    1_
$a Suzuki, Kenshi $u Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan $1 https://orcid.org/0000000171325337
700    1_
$a Hulin, Cyrille $u Department of Hematology, University Hospital Bordeaux, Bordeaux, France
700    1_
$a Garg, Mamta $u Department of Haematology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
700    1_
$a Quach, Hang $u Department of Haematology, St. Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia $1 https://orcid.org/0000000247963352
700    1_
$a Sia, Hanlon $u Cancer Care & Haematology Unit, The Tweed Hospital, Tweed Heads, NSW, Australia
700    1_
$a George, Anup $u Wellington Blood and Cancer Center, Wellington, New Zealand
700    1_
$a Konstantinova, Tatiana $u Hematology Department, Regional Hospital #1, Ekaterinburg, Russia $1 https://orcid.org/0000000346870784
700    1_
$a Risse, Marie-Laure $u Sanofi Research and Development, Vitry-Sur-Seine, France
700    1_
$a Asset, Gaelle $u Sanofi Research and Development, Chilly-Mazarin, France
700    1_
$a Macé, Sandrine $u Sanofi Research and Development, Vitry-Sur-Seine, France $1 https://orcid.org/0000000192636994
700    1_
$a van de Velde, Helgi $u Sanofi, Cambridge, MA; and
700    1_
$a Moreau, Philippe $u Department of Hematology, University Hospital of Nantes, Nantes, France
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 6, č. 15 (2022), s. 4506-4515
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35594559 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031101304 $b ABA008
999    __
$a ok $b bmc $g 1854532 $s 1176156
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 6 $c 15 $d 4506-4515 $e 20220809 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace